Most labs rely on dry ice to transport cryopreserved cells between labs. But what if that “cold” transport method is doing more harm than good? Dry ice is -80°C—far warmer than the critical -135°C threshold where biological activity truly halts. The shock from that temperature gap can impair or even kill cells, especially during repeat freeze-thaw cycles.
In this second installation of “Ever Sample Matters”, we explore the hidden risks of dry ice, the science of the glass transition point, and the smarter way to protect your cryopreserved material.
Watch now to learn how to upgrade your cold chain and safeguard every cell.
About the Author
Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems. Azenta is headquartered in Burlington, MA, with operations in North America, Europe, and Asia.
